Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Glyx-13 Peptide
2. Tppt-amide
1. 117928-94-6
2. Tppt-amide
3. Glyx 13
4. Glyx13
5. Glyx-13
6. Rapastinelum
7. L-threoninamide, L-threonyl-l-prolyl-l-prolyl-
8. Glyx-13 Trifluoroacetate
9. 6a1x56b95e
10. (2s)-1-[(2s)-1-[(2s,3r)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
11. Glyx-13 Peptide
12. Rapastinel [usan:inn]
13. Unii-6a1x56b95e
14. (s)-n-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((s)-1-((2s,3r)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide
15. Glyx13;rapastinel
16. Rapastinel(glyx-13)
17. Thr-pro-pro-thr-nh2
18. Rapastinel [inn]
19. Rapastinel [usan]
20. Rapastinel (glyx-13)
21. Rapastinel [who-dd]
22. Schembl1668190
23. Chembl3544917
24. Ex-a794
25. Dtxsid501030481
26. Mfcd12912477
27. S6907
28. Zinc71773625
29. Akos024457610
30. Cs-5507
31. Db11801
32. Ncgc00485669-01
33. Ac-32874
34. As-55920
35. Hy-16728
36. L-threonyl-l-prolyl-l-prolyl-l-threoninamide
37. Q5513673
38. (s)-1-(l-threonyl-l-prolyl)-n-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)pyrrolidine-2-carboxamide
| Molecular Weight | 413.5 g/mol |
|---|---|
| Molecular Formula | C18H31N5O6 |
| XLogP3 | -2.8 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 7 |
| Exact Mass | 413.22743373 g/mol |
| Monoisotopic Mass | 413.22743373 g/mol |
| Topological Polar Surface Area | 179 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 659 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
65
PharmaCompass offers a list of Rapastinel API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rapastinel manufacturer or Rapastinel supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rapastinel manufacturer or Rapastinel supplier.
PharmaCompass also assists you with knowing the Rapastinel API Price utilized in the formulation of products. Rapastinel API Price is not always fixed or binding as the Rapastinel Price is obtained through a variety of data sources. The Rapastinel Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A GLYX 13 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of GLYX 13, including repackagers and relabelers. The FDA regulates GLYX 13 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. GLYX 13 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of GLYX 13 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A GLYX 13 supplier is an individual or a company that provides GLYX 13 active pharmaceutical ingredient (API) or GLYX 13 finished formulations upon request. The GLYX 13 suppliers may include GLYX 13 API manufacturers, exporters, distributors and traders.
click here to find a list of GLYX 13 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
GLYX 13 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of GLYX 13 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right GLYX 13 GMP manufacturer or GLYX 13 GMP API supplier for your needs.
A GLYX 13 CoA (Certificate of Analysis) is a formal document that attests to GLYX 13's compliance with GLYX 13 specifications and serves as a tool for batch-level quality control.
GLYX 13 CoA mostly includes findings from lab analyses of a specific batch. For each GLYX 13 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
GLYX 13 may be tested according to a variety of international standards, such as European Pharmacopoeia (GLYX 13 EP), GLYX 13 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (GLYX 13 USP).
